Listing Regulation – ASCELIA

All All press releases Regulatory press releases Financial reports

Regulatory

2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals

Regulatory

2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022

Regulatory

2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB

Regulatory

2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent

Regulatory

2021-11-30 | Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB

Regulatory

2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration

Regulatory

2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch

Regulatory

2021-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021

Regulatory

2021-04-15 | Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm

Regulatory

2021-04-13 | Bulletin from the extraordinary general meeting in Ascelia Pharma AB

Regulatory

2021-04-09 | Issue and repurchase of series C shares for share saving program

Regulatory

2021-03-31 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB

Regulatory

2021-03-17 | Notice of extraordinary general meeting in Ascelia Pharma

Regulatory

2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study

Regulatory

2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch

Regulatory

2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE

Regulatory

2020-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2020

Regulatory

2020-04-03 | Ascelia Pharma’s Nomination Committee proposes election of Lauren Barnes to the Board of Directors